<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916030</url>
  </required_header>
  <id_info>
    <org_study_id>IRB0000871535</org_study_id>
    <nct_id>NCT02916030</nct_id>
  </id_info>
  <brief_title>Vitamin D and Stroke</brief_title>
  <official_title>Vitamin D and Stroke: A Comparative Study to Risk Factors and Stroke Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke remains one of the most devastating neurological diseases, often causing death, or
      gross physical impairment. It is the second most common cause of death worldwide and a major
      cause of acquired disability in adults.Vitamin D deficiency has been reported to contribute
      to the risk of cardiovascular disease especially stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This case -control observational prospective study will conducted on fifty patients with
      first -ever acute onset stroke within seven days (25 patients with hemorrhagic stroke and 25
      patients with ischemic stroke )
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">January 3, 2017</completion_date>
  <primary_completion_date type="Actual">January 2, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum 25 (OH) D levels</measure>
    <time_frame>Within the first 24 hours</time_frame>
    <description>serum 25 (OH) D levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke severity</measure>
    <time_frame>Within the first 24 hours</time_frame>
    <description>Stroke severity will be assessed by Scandinavian Stroke scale Stroke (SSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke etiology</measure>
    <time_frame>Within the first 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke risk factors</measure>
    <time_frame>Within the first 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke subtypes</measure>
    <time_frame>Within the first 24 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Group 1 (hemorrhagic stroke)</arm_group_label>
    <description>All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Ischemic stroke)</arm_group_label>
    <description>All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vit D</intervention_name>
    <description>It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types</description>
    <arm_group_label>Group 1 (hemorrhagic stroke)</arm_group_label>
    <arm_group_label>Group 2 (Ischemic stroke)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with first -ever acute onset stroke within seven days
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Onset is within one week

          -  Confirmed stroke by brain CAT and / or MRI scan either haemorrhage or infarction

        Exclusion Criteria:

          -  Cognitive and mental changes

          -  Recurrent stroke

          -  Hepatic and renal impairment

          -  Endocrinal diseases

          -  Steroid therapy

          -  Vitamin D or Ca supplementation

          -  Previous fractures

          -  Bone diseases

          -  brain neoplasm,

          -  Autoimmune diseases

          -  History of acute and chronic inflammatory diseases

          -  Malignancy,

          -  Trauma

          -  Surgery

          -  Acute vascular diseases that occurred within four weeks prior the onset of stroke

          -  History myocardial infarction Ë‚3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>sayed abd elshafy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>associate professor of anesthesia and critical care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <zip>74111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 17, 2016</study_first_submitted>
  <study_first_submitted_qc>September 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Sayed Kaoud Abd-Elshafy</investigator_full_name>
    <investigator_title>Associate Professor (Anesthesiology and Critical Care)- College of Medicine-Assiut University</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Stroke</keyword>
  <keyword>Parathormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

